12
NEWS
Our free online magazine
for people with diabetes
sent to your inbox each month.
News, views, reviews, features,
free samples and giveaways.
Sign up with your email address!
ISSUE 115
MAKING
CARBS
COUNT
MILK ALTERNATIVES
PLUS Diabetes kit • Giveaways • News (for T1 and T2) • Food News
JUDGEMENT
CALL
10 things to consider when
choosing a meter
PLUS
Who's Zooming who?
An update on digital
health delivery
ISSUE 111
MAKING
CARBS
COUNT
BELL PEPPERS
PLUS Diabetes kit • Giveaways • News (for T1 and T2) • Food News
COMFORT
ZONE
Roche's new micropump:
designed for user satisfaction
PLUS
Dexcom's next
generation G7 sensor ISSUE 119
MAKING
CARBS
COUNT
LUSCIOUS LYCHEES
PLUS Diabetes kit • Giveaways • News (for T1 and T2) • Food News
DIY SYSTEMS
The ultimate in self-care?
PLUS
Roche's new
meter launch:
introducing
the Accu-Chek
Instant
email address
now it would seem. The new tool
was created to tackle the challenge
of which drug to choose after
metformin had been prescribed - it
is know that in time, many drugs can
become less effective, leading to the
need for more, different medications.
The Exeter 5-drug T2D model
was developed and tested using data
from 1m people with T2D in the UK,
linking GP and hospital records ¬-
its accuracy verified with data from
clinical trials.
Modelling showed that starting
people on the drug recommended by
the new tool could lead to marked
reductions in blood glucose levels
(HbA1c) at one year, of around
5mmol/mol on average. Importantly,
these improvements in blood glucose
levels could approximately double
the time until people need to start
taking further diabetes medications.
The Exeter 5-drug T2D model use
was also predicted to lower risks
of developing serious long-term
diabetes complications.
Using routinely collected clinical
information, the tool offers a lowcost,
practical, immediately usable
solution that could significantly
improve the treatment of T2D.
The tool's performance in clinical
practice is currently being assessed
in 22,500 people with T2D across
Scotland, which will inform its
roll-out across the UK and globally,
enabling a new era of personalised
treatment for people with T2D.
For the first time,
our model allows
people living with
T2D to quickly
identify the best
treatment to
manage their
blood glucose
levels, helping
reduce their
risk of diabetes
complications. ~
Dr John Dennis
worldwide. For the first time, our
model allows people living with T2D
to quickly identify the best treatment
to manage their blood glucose levels,
helping reduce their risk of diabetes
complications. This offers a major
advance on the current approach
to choosing diabetes medications.
Following on from the paper coming
out, we are looking to build the
evidence to integrate the calculator
in the NHS as soon as possible, this
may involve a trial and assessing
cost-effectiveness. In the meantime,
we have a web calculator that can be
tried out on our website.
Professor Andrew Hattersley
from the University of Exeter,
added, "Critically, our model can
be implemented in clinical care
immediately and at no additional
cost. This is because it uses simple
measures such as sex, weight
and standard blood tests that are
performed routinely. We hope that
we can roll out the model quickly to
make it available to help people with
T2D in the UK and across the world."
The research paper, A fivedrug class model using routinely
available clinical features to optimise
prescribing in type 2 diabetes: a
prediction model development and
validation study, and is published in
The Lancet.
The Exeter 5-drug T2D model
tool can be viewed at www.
diabetesgenes.org
It's personal
Dr John Dennis, Associate
Professor at the University of Exeter
who led the study, explains, "We
have developed a completely new
personalised approach for diabetes
treatment, that could benefit
everyone with T2D in the UK and